The US Centers for Medicare and Medicaid Services (CMS) recently agreed with diagnostic sponsor T2 Biosystems Inc. that the company’s T2Bacteria panel meets all of the agency’s qualifications for an additional new technology add-on payment (NTAP). It will apply the add-on payment starting in October.
T2Bacteria Panel Wins CMS Approval For New Tech Add-On Payment
The US Medicare agency approved a new technology add-on payment (NTAP) for T2 Biosystems’ blood test, the T2Bacteria panel, for the fiscal year that will begin on 1 October.
More from Policy & Regulation
More from Medtech Insight
• By
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
• By
At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.
• By
A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.